These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17978751)

  • 1. [Protein glycation and endothelium dysfunction].
    Grossin N; Wautier JL
    J Soc Biol; 2007; 201(2):175-84. PubMed ID: 17978751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein glycation: a firm link to endothelial cell dysfunction.
    Wautier JL; Schmidt AM
    Circ Res; 2004 Aug; 95(3):233-8. PubMed ID: 15297385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced glycation end-products and atherosclerosis.
    Vlassara H
    Ann Med; 1996 Oct; 28(5):419-26. PubMed ID: 8949973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses.
    Basta G; Lazzerini G; Massaro M; Simoncini T; Tanganelli P; Fu C; Kislinger T; Stern DM; Schmidt AM; De Caterina R
    Circulation; 2002 Feb; 105(7):816-22. PubMed ID: 11854121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
    Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
    Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
    Schmidt AM; Yan SD; Wautier JL; Stern D
    Circ Res; 1999 Mar; 84(5):489-97. PubMed ID: 10082470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advanced glycation end products: A risk factor for human health].
    Wautier MP; Tessier FJ; Wautier JL
    Ann Pharm Fr; 2014 Nov; 72(6):400-8. PubMed ID: 25438650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes and advanced glycation endproducts.
    Vlassara H; Palace MR
    J Intern Med; 2002 Feb; 251(2):87-101. PubMed ID: 11905595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE.
    Wautier MP; Chappey O; Corda S; Stern DM; Schmidt AM; Wautier JL
    Am J Physiol Endocrinol Metab; 2001 May; 280(5):E685-94. PubMed ID: 11287350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].
    Nawroth PP; Bierhaus A; Vogel GE; Hofmann MA; Zumbach M; Wahl P; Ziegler R
    Med Klin (Munich); 1999 Jan; 94(1):29-38. PubMed ID: 10081287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.
    Sourris KC; Watson A; Jandeleit-Dahm K
    Handb Exp Pharmacol; 2021; 264():395-423. PubMed ID: 32809100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure.
    Aronson D
    Med Hypotheses; 2002 Sep; 59(3):297-301. PubMed ID: 12208156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of AGEs-RAGE system in cardiovascular disease.
    Fukami K; Yamagishi S; Okuda S
    Curr Pharm Des; 2014; 20(14):2395-402. PubMed ID: 23844818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red blood cell adhesion in diabetes mellitus is mediated by advanced glycation end product receptor and is modulated by nitric oxide.
    Grossin N; Wautier MP; Wautier JL
    Biorheology; 2009; 46(1):63-72. PubMed ID: 19252229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the AGE-RAGE system in vascular injury in diabetes.
    Yamamoto Y; Yamagishi S; Yonekura H; Doi T; Tsuji H; Kato I; Takasawa S; Okamoto H; Abedin J; Tanaka N; Sakurai S; Migita H; Unoki H; Wang H; Zenda T; Wu PS; Segawa Y; Higashide T; Kawasaki K; Yamamoto H
    Ann N Y Acad Sci; 2000 May; 902():163-70; discussion 170-2. PubMed ID: 10865836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
    Yamagishi S; Nakamura K; Matsui T
    Curr Drug Discov Technol; 2006 Mar; 3(1):83-8. PubMed ID: 16712466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
    Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
    Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation end products and the progressive course of renal disease.
    Heidland A; Sebekova K; Schinzel R
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S100-6. PubMed ID: 11576932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced glycation end products and vascular structure and function.
    Soldatos G; Cooper ME
    Curr Hypertens Rep; 2006 Dec; 8(6):472-8. PubMed ID: 17087858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aging: role and control of glycation].
    Boulanger E; Puisieux F; Gaxatte C; Wautier JL
    Rev Med Interne; 2007 Dec; 28(12):832-40. PubMed ID: 17597260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.